CLINICAL_TRIALS
trial_result
· 2021-08-18
Clinical Trial Update: Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL [Phase 2]
Summary
Phase 2 trial evaluating acalabrutinib in patients with relapsed/refractory and treatment-naïve deletion 17p chronic lymphocytic leukemia/small lymphocytic lymp…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Acerta Pharma BV | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-08-18